Entry

D11055                      Drug

Name

Fremanezumab (USAN/INN);
Fremanezumab (genetical recombination) (JAN);
Fremanezumab-vfrm;
Ajovy (TN)

Product

AJOVY (Teva Pharmaceuticals USA)

Formula

C6470H9952N1716O2016S46

Exact mass

145415.6128

Mol weight

145505.5255

Sequence

(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFS NYWISWVRQA PGKGLEWVAE IRSESDASAT
HYAEAVKGRF TISRDNAKNS LYLQMNSLRA EDTAVYYCLA YFDYGLAIQN YWGQGTLVTV
SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
SSGLYSLSSV VTVPSSNFGT QTYTCNVDHK PSNTKVDKTV ERKCCVECPP CPAPPVAGPS
VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVQFNWYV DGVEVHNAKT KPREEQFNST
FRVVSVLTVV HQDWLNGKEY KCKVSNKGLP SSIEKTISKT KGQPREPQVY TLPPSREEMT
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPMLD SDGSFFLYSK LTVDKSRWQQ
GNVFSCSVMH EALHNHYTQK SLSLSPGK
(Light chain)
EIVLTQSPAT LSLSPGERAT LSCKASKRVT TYVSWYQQKP GQAPRLLIYG ASNRYLGIPA
RFSGSGSGTD FTLTISSLEP EDFAVYYCSQ SYNYPYTFGQ GTKLEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H98, H136-L214, H149-H205, H224-H'224, H225-H'225, H228-H'228, H231-H'231, H262-H322, H368-H426, H'22-H'98, H'136-L'214, H'149-H'205, H'262-H'322, H'368-H'426, L23-L88, L134-L194, L'23-L'88, L'134-L'194)

Type

Peptide

Remark

Therapeutic category:

1190

ATC code:

N02CD03

Product:

D11055<JP/US>

Efficacy

Antimigraine, Anti-calcitonin gene related peptide (GCRP) antibody

Comment

Monoclonal antibody

Target

CALCA (CGRP) [HSA:796] [KO:K12332]

Pathway

hsa04080

Neuroactive ligand-receptor interaction

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
  N02 ANALGESICS
   N02C ANTIMIGRAINE PREPARATIONS
    N02CD Calcitonin gene-related peptide (CGRP) antagonists
     N02CD03 Fremanezumab
      D11055  Fremanezumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antimigraine Agents
  Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
   Fremanezumab
    D11055  Fremanezumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1  Agents affecting nervous system and sensory organs
  11  Agents affecting central nervous system
   119  Miscellaneous
    1190  Miscellaneous
     D11055  Fremanezumab (USAN/INN); Fremanezumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
  Organismal systems
   Circulatory system
    CALCA (CGRP)
     D11055  Fremanezumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D11055
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D11055
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D11055
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D11055

Other DBs

CAS:	1655501-53-3

PubChem:

363669768